abelacimab

不足 26% 的中国房颤患者接受抗凝剂治疗，而在日本近三分之一的患者未得到充分治疗 在中国约 63% 的癌症患者在确诊后的前 6 个月内出现静脉血栓栓塞症 Abelacimab 已在 23 个国家/地区进行研究 包括北美、欧洲和亚太地区的其他地方 马萨诸塞州剑桥市, June 09, 2023 (GLOBE NEWSWIRE) -- Anthos…

Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer…

FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third…

This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor…

A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University's Jeffrey Weitz.…

"Patients who undergo knee replacement routinely receive anti-clotting treatment with enoxaparin or other anticoagulant medications that require daily administration," Jeffrey Weitz said. …